Search results - Portal of Medical Data Models (MDM-Portal)

Eligibility Early Rheumatoid Arthritis NCT01768923

- 12/21/18 - 1 form, 2 itemgroups, 9 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

Early RA Vascular Randomised Controlled Study; ODM derived from: https://clinicaltrials.gov/show/NCT01768923

Eligibility Rheumatoid Arthritis NCT01270087

- 6/20/17 - 1 form, 2 itemgroups, 12 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.; ODM derived from: https://clinicaltrials.gov/show/NCT01270087

dbGaP phs000944 eMERGE Clinical Center at Partners HealthCare - Eligibility

- 11/27/24 - 6 forms, 2 itemgroups, 11 items, 1 language

Itemgroups: IG.elig, IG.elig

Principal Investigator: Scott T. Weiss, MD, MS, Partners HealthCare System, Boston, MA, USA MeSH: Hypercholesterolemia,Asthma,Arthritis, Rheumatoid,Attention Deficit Disorder with Hyperactivity,Bipolar Disorder,Coronary Disease,Depression,Heart Failure,Inflammatory Bowel Diseases,Multiple Sclerosis,Schizophrenia,Stroke https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000944 The Partners HealthCare Biobank is a large research data and sample repository working within the framework of Partners Personalized Medicine. It provides researchers access to high quality, consented samples to help foster research, advance understanding of the causes of common diseases, and advance the practice of medicine. The Partners Biobank provides banked samples (plasma, serum and DNA) collected from consented patients. These samples are available for distribution to Partners HealthCare investigators with appropriate approval from the Partners Institutional Review board (IRB). They are linked to clinical data that originates in the Electronic Medical Record (EMR), as well as additional health information collected in a self-reported survey. The Partners Biobank will be genotyping 25,000 subjects with the Illumina Multiethnic Beadchip 1.6 million SNPs with exome and custom content ( 60,000 LoFs). Of the participants genotyped so far, 4929 of 4962 (99.3%) individuals have genotype data that passed the default quality thresholds for the Infinium array (call rate = 0.99). We are submitting the genotype data to dbGaP for 4929 subjects with 12 phenotypes (based on icd9 codes). We will do annual releases until we reach the full 25,000 genotyped subjects.

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Early Withdrawal - Administrative; Pain Assessment VAS Score; Patient's Global Assessment of Arthritis Condition VAS Score; Physician's Global Assessment of Arthritis Condition VAS Score; Vital Signs; ECG; Neurological Examination

- 3/24/20 - 1 form, 7 itemgroups, 21 items, 1 language

Itemgroups: Administrative, Pain Assessment VAS Score , Patient's Global Assessment of Arthritis Condition VAS Score , Physician's Global Assessment of Arthritis Condition VAS Score, Vital Signs , ECG , Neurological Examination

Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Unscheduled - PK Blood Sample; Tender Joint Count; Swollen Joint Count; Swollen/Tender Joint Count; Pain Assessment VAS Score; Patient's Global Assessment of Arthritis Condition VAS Score; Physician's Global Assessment of Arthritis Condition VAS Score

- 3/24/20 - 1 form, 13 itemgroups, 32 items, 1 language

Itemgroups: PK Blood Sample - Point in Time Collection , Tender Joint Count Page 1, Tender Joint Count Page 2 , Joint Assessor Initials - Joint Pain/Tenderness , Calculations - Joint Pain/Tenderness, Swollen Joint Count Page 1, Swollen Joint Count Page 2, Joint Assessor Initials - Joint Swelling , Calculations - Joint Swelling , Swollen/ Tender Joint Count, Pain Assessment VAS Score , Patient's Global Assessment of Arthritis Condition VAS Score , Physician's Global Assessment of Arthritis Condition VAS Score

Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid